Chicago-based biofabrication company Dimension Inx has been granted a U.S. patent covering its 3D-Painting System, a platform built for designing and manufacturing next-gen biomaterials for organ and tissue repair and regeneration. The company says the patent issuance strengthens its position on the market by showcasing the differentiation of its biomaterials offering.
The biofabrication company was born out of biomaterials research pioneered by co-founders Ramille Shah, PhD, and Adam Jakus, PhD, at Northwestern University’s Tissue Engineering and Additive Manufacturing Lab. The pair developed a portfolio of biomaterials over nearly a decade before spinning off with Dimension Inx, which now holds exclusive worldwide rights to commercialize the 3D-Painting System and associated materials.
Dimension Inx’s now patent-protected 3D-Painting System is capable of high loading bioactive ingredients and rapid printing of biomaterials. Notably, the platform is designed to dry at room temperature, effectively eliminating the need for sintering—which can effect bioactivity—and other processing techniques like cross-linking. According to the company, these capabilities are “critical for conferring the necessary composition and microstructure of surgical implants that promote healing and tissue regeneration.”
The rapid printing rates of the 3D-Painting System also mean that the process is scalable and is suitable for commercial production of novel medical products.
“As we move toward the clinic with our first medical products, this patent strengthens the differentiation and defensibility of our biomaterials platform,” explained Caralynn Nowinski Collens, MD, CEO of Dimension Inx. “Further, it advances our mission of delivering regenerative medical products to the patients that need them by being the industry partner of choice for biomaterials design and production.”
The patent is U.S. Patent No. 10,584,254 “A Universal Method for Production and 3D-Printing of High-Particle-Content 3D-Inks,” and covers Dimension Inx’s compositions, materials and methods for producing and 3D printing high-particle-content 3D inks. Dimension Inx also hold similar patents in Japan (P6542807) and Australia (AU2015258978).
“The award of this patent recognizes the novelty and value of the 3D-Painting System,” said Dr. Jakus, CTO at Dimension Inx. “The innovation protected here overcomes hurdles faced by other 3D printing and bioprinting methods and enables, for the first time, the ability to create and rapidly 3D print an extensive range of biomaterials without heat or other processing techniques that limit or destroy bioactivity.”
Today, Dimension Inx’s biomaterials, including Hyperelastic Bone and 3D-Graphene & Graphite, can be purchased through one of its many partners, such as Advanced BioMatrix, Advanced Solutions Life Sciences, Allevi and Millipore Sigma.